Baili Tianheng announced that the phase III clinical trial for advanced or metastatic non-squamous non-squamous non-small cell lung cancer with first-line HER2 mutations compared to t-Bren, an innovative biopharmaceutical independently developed by the company compared with pabolizumab combined with platinum-containing chemotherapy, has recently completed the enrollment of the first test subjects. t-Bren is an innovative ADC targeting HER2 and has shown significant anti-tumor efficacy in clinical trials. Currently, T-Bren is conducting 14 clinical trials at home and abroad, including 5 phase III, 1 phase II/III, 2 phase II, 3 phase I/II, and 3 phase I clinical trials, covering various indications.

Baili Tianheng announced that the phase III clinical trial for advanced or metastatic non-squamous non-squamous non-small cell lung cancer with first-line HER2 mutations compared to t-Bren, an innovative biopharmaceutical independently developed by the company compared with pabolizumab combined with platinum-containing chemotherapy, has recently completed the enrollment of the first test subjects. t-Bren is an innovative ADC targeting HER2 and has shown significant anti-tumor efficacy in clinical trials. Currently, T-Bren is conducting 14 clinical trials at home and abroad, including 5 phase III, 1 phase II/III, 2 phase II, 3 phase I/II, and 3 phase I clinical trials, covering various indications.